Weekly Cetuximab Maintenance Dose
The recommended weekly maintenance dose of cetuximab (Erbitux) for adult patients is 250 mg/m² administered intravenously over 60 minutes, following an initial loading dose of 400 mg/m² given over 2 hours. 1
Standard Dosing Regimen
The established dosing schedule consists of:
- Loading dose: 400 mg/m² IV over 2 hours (first infusion only)
- Maintenance dose: 250 mg/m² IV over 60 minutes weekly thereafter
This weekly (Q1W) regimen has been validated across multiple clinical settings including metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma, as demonstrated in pivotal trials such as CRYSTAL, TAILOR, and CO.17 1.
Alternative Biweekly Dosing
An every-2-weeks (Q2W) schedule has been approved as an alternative:
- 500 mg/m² IV over 2 hours every 2 weeks (no separate loading dose required) 1
This Q2W regimen offers improved convenience by synchronizing with chemotherapy schedules and reducing infusion burden. Pharmacometric modeling demonstrates clinical non-inferiority between Q2W and Q1W dosing, with indistinguishable tumor shrinkage and survival outcomes 2. The Q2W schedule is particularly practical when combined with FOLFOX or FOLFIRI regimens that are administered every 2 weeks.
Clinical Context and Combinations
First-Line Metastatic Colorectal Cancer
When combined with chemotherapy (FOLFIRI or FOLFOX) in RAS wild-type mCRC, cetuximab follows the standard weekly maintenance dosing of 250 mg/m² after the 400 mg/m² loading dose 1. This combination is particularly effective in left-sided primary tumors.
Monotherapy
As single-agent therapy (third-line or beyond), the same dosing applies: 400 mg/m² loading dose followed by 250 mg/m² weekly 1.
Important Caveats
Infusion reactions: The first dose carries the highest risk of infusion reactions. Premedication with antihistamines is recommended, and patients should be monitored for at least 1 hour post-infusion 3.
Skin toxicity monitoring: Approximately 89% of patients develop skin toxicity, with 32.6% experiencing grade 3-4 reactions 4. This is often dose-limiting and requires proactive management.
RAS/BRAF testing mandatory: Cetuximab should only be used in patients with confirmed RAS wild-type tumors, as KRAS mutations are associated with significantly worse outcomes (HR for OS = 0.458, p=0.01) 5.
Primary tumor location matters: Cetuximab demonstrates superior efficacy in left-sided versus right-sided colon cancers. Right-sided RAS wild-type tumors may benefit more from bevacizumab-based regimens 1.
The weekly 250 mg/m² maintenance dose remains the gold standard, though the Q2W alternative provides a validated option when logistical considerations or chemotherapy synchronization favor less frequent administration.